R
RLMD
Relmada Therapeutics Inc
7.64
+0.12+1.60%After Hours: 7.51 -0.13 -1.70%18:42 05/01 EDT
OPEN/PREV CLOSE7.49/7.41
TODAY RANGE7.18-7.63
VOL719.37K
MARKET CAP770.94M
52 WEEK RANGE0.3233-7.94
AVG VOL (3M)1.84M
% TURNOVER0.69%
TURNOVER0
P/E (TTM)-5.0568
% RANGE6.07%
EPS(TTM)-1.4535
P/E(FORWARD)-9.4231
P/B6.23
BVPS1.180
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP461.25M
SHARES OUTSTANDING104.89M
NEXT EARNINGS05/11-05/15
FREE FLOAT62.75M
LOT SIZE1
EX-DATE09/30/2019
News
Press Releases
Financial Reports
Profile
TipRanks·04/08 02:15
Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)
Reuters·04/06 20:36
Relmada Therapeutics announces annual shareholder meeting via webcast
NASDAQ·04/02 14:00
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Seeking Alpha·03/30 19:16
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See
Reuters·03/30 07:01
PreveCeutical appoints Dr. Raj S. Pruthi to board of directors
Seeking Alpha·03/24 18:31
Relmada wins bullish view at Piper Sandler on cancer therapy
Dow Jones·03/24 13:05
Relmada Therapeutics Price Target Announced at $12.00/Share by Piper Sandler
TipRanks·03/24 09:00
Relmada Therapeutics initiated with an Overweight at Piper Sandler
Reuters·03/24 07:39
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco
TipRanks·03/21 00:05
Relmada Therapeutics Charts Aggressive Path After Earnings Call
TipRanks·03/20 21:21
Relmada Highlights NDV-01 Data, Funding in 2025 Results
Dow Jones·03/20 13:54
Relmada Therapeutics Price Target Raised to $19.00/Share From $10.00 by Mizuho
Dow Jones·03/20 13:54
Relmada Therapeutics Is Maintained at Outperform by Mizuho
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.